Updated:
T.Rx Capital
T.Rx Capital is a private equity firm headquartered in Boston, Massachusetts, specializing in early-stage investments. The firm targets seed and startup-stage...
T.Rx Capital
T.Rx Capital is a private equity firm headquartered in Boston, Massachusetts, specializing in early-stage investments. The firm targets seed and startup-stage companies, focusing its origination engine on the intersection of healthcare services, digital health, and life sciences technology, a profile consistent with the dense biotech and academic innovation cluster that defines the Cambridge-Boston corridor. The firm's strategy centers on direct equity investments at the earliest phases of company formation. Its mandate covers seed rounds and startup financings, positioning T.Rx Capital to enter cap tables alongside angel syndicates and pre-seed venture funds. The firm has maintained a deliberately low public profile, with no disclosed track record of institutional fund closes or named portfolio exits available in public filings, suggesting disciplined balance-sheet investing or a tightly held limited-partner base. T.Rx Capital operates a lean structure, consistent with firms deploying niche capital into technical seed-stage ventures. While specific professional headcount and the names of its investment partners have not been widely published, the firm's Boston location places it within the New England life-sciences and academic-origination ecosystem. The firm maintains no other publicized adjacencies such as philanthropic foundations, operator networks, or real-asset subsidiaries. The firm's structural differentiator lies in its discretion. T.Rx Capital operates without the media footprint of a traditional institutional fundraiser, a model that can offer founders a quiet capital partner during the fragile seed and startup phases of company building where competitive visibility is often unwelcome.
General information
Firm type
Private Equity
Year founded
2023
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Dr. Robert Langer ScD
Executive Chairman & Chair of Scientific Advisory Board
Dr. Kwesi Frimpong-Boateng PhD, MBA
Co-founder & Managing Partner
Michael Langer
Co-founder & Managing Partner
Dr. Corey McCann MD, PhD
Co-founder & Managing Partner
Dr. Liz Kwo MD, MBA, MPH
Venture Partner
Dr. Debbie W. Lin PhD
Venture Partner
Dan O'Neill
Fractional COO
Sector focus
Frequently asked questions
Who runs investment decisions at T.Rx Capital?
The four Co-Founding Managing Partners — Dr. Robert Langer (Executive Chairman), Dr. Kwesi Frimpong-Boateng, Michael Langer, and Dr. Corey McCann — collectively lead investment decisions. Venture Partners Dr. Liz Kwo and Dr. Debbie Lin contribute deal sourcing and diligence support. The advisory board, which includes Third Rock Ventures founder Mark Levin and former Pfizer Chief Medical Officer Freda Lewis-Hall, provides scientific and strategic counsel on opportunities.
How does T.Rx Capital source proprietary deal flow?
The firm's primary sourcing advantage flows from Executive Chairman Robert Langer's MIT laboratory, the largest biomedical engineering lab in the world with over 100 researchers and $17 million in annual grants. His network of 1,500 patents licensed to more than 400 companies, plus the other partners' relationships across Eli Lilly, Pear Therapeutics and McKinsey, creates an early-stage healthcare pipeline that is difficult for generalist seed funds to replicate.
Is T.Rx Capital structured as a single family office or a traditional venture firm?
T.Rx Capital is structured as a private equity firm managing T.Rx Fund 1, a closed early-stage healthcare fund. It is not a family office. Michael Langer previously operated Old Silver VC, a family investment firm focused on healthcare and deeptech, but T.Rx Capital is a distinct, fund-based manager with external limited partners.
Does T.Rx Capital participate in fund commitments or only direct deals?
The firm makes direct investments into early-stage healthcare companies. There is no disclosed fund-of-funds program or limited partner commitment strategy. The team's prior experience at venture funds and corporate venture arms suggests a pure direct-investment model.
What investment stages does T.Rx Capital typically target?
T.Rx Capital targets the seed stage exclusively, often acting as a company's first or earliest institutional investor. The firm has created at least one NewCo internally — a stealth company addressing intractable pain — indicating a willingness to incubate companies from inception rather than waiting for a formed startup.
Which sectors does T.Rx Capital explicitly avoid?
T.Rx Capital does not publish an explicit exclusion list. Given its exclusive focus on healthcare, the firm implicitly avoids consumer, enterprise software, industrials, and other non-health verticals. Within healthcare, the disclosed portfolio — Recuro, Zus, a radiopharmaceuticals company, and a pain NewCo — signals conviction across biotech, digital health, and medtech without an obvious avoidance of any subsector.
Does T.Rx Capital maintain philanthropic structures, and how are they separated?
Principal Michael Langer serves as Senior Advisor of Special Projects at the Galenus Foundation and sits on the board of the Terasaki Institute for Biomedical Innovation. Analyst Pranav Seshadri holds board and strategy roles at the Sena Institute of Technology Foundation and Solvandria Foundation. These are personal affiliations, not firm vehicles. T.Rx Capital itself does not disclose a foundation or grantmaking arm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: